Online test of BlinkLab Dx1 for autism in kids aged 2–11
Official title: Online Evaluation of the Diagnostic Accuracy of BlinkLab's Digital Assessments for Autism
Run by Blinklab Limited · NCT07590973 · Data updated 2026-11-12
This study tests whether the BlinkLab Dx1 smartphone app can help identify autism in children aged 2 to 11 by comparing app-based measurements with prior clinical diagnoses.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 2 Years to 11 Years |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Blinklab Limited Industry-sponsored |
| Locations | 1 site (Princeton, New Jersey) |
| Status | Recruiting |
| Started | February 15, 2025 |
| Main results expected | September 1, 2026 |
| Study ends | December 1, 2026 |
| Registry record updated | May 15, 2026 |
| Trial ID | NCT07590973 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children aged 2 to 11 who recently completed a DSM-5 neurodevelopmental assessment within the past 12 months and whose caregivers can use a smartphone and English language.
✕Probably not a fit
Children without a definitive DSM-5 diagnosis or those whose assessments were not recent may derive little to no benefit from the app-based approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study collects remote BlinkLab Dx1 measurements during short video sessions and caregiver reports from children who recently had a neurodevelopmental assessment. The app records reflexive sensorimotor responses and patterns of repetitive behavior while children watch and listen to stimuli, and caregivers complete a brief questionnaire. Researchers will compare these digital measurements with DSM-5-based diagnoses from routine care to develop a machine learning model that classifies participants as Positive for autism, Intermediate, or Negative for autism. The primary diagnostic analyses exclude intermediate results to focus on definitive positive or negative classifications. Data are gathered retrospectively for the clinical reference standard and prospectively for the app measurements, with model development and testing done on separate datasets.
Why it matters
Potential benefit: If successful, the app-based approach could support clinicians in identifying autism more efficiently using remote, non-invasive measures.
How similar studies have gone: Prior digital and sensor-based approaches show potential in supporting autism screening, but this exact smartphone-based matching with retrospective clinical standards is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age: Children between 2 to 11 years old 2. Parent/Caregiver/Healthcare Provider Concern: The child has received a diagnostic outcome of a neurodevelopmental assessment based on DSM-5 criteria within the past 12 months. 3. Language Proficiency: Parents and subjects must have functional English capability in the home environment. 4. Informed Consent: Parents must be able to read, understand, and voluntarily sign the Informed Consent Form (ICF). 5. Videotaping: subjects must be willing to be videotaped during the diagnostic assessment by the BlinkLab App. Exclusion Criteria: 1. Device Compatibility: Parents without smartphone capabilities necessary for using the BlinkLab app. 2. Previous Enrollment: Subjects who have been previously enrolled in any BlinkLab clinical study. 3. Location of at home testing: Not being able to complete all remote at-home study sessions within the US. 4. History of audiogenic seizures: Participants with a known history of seizures that are triggered by auditory stimuli, including reflex or startle epilepsy provoked by sounds (audiogenic seizures), or any other form of sound-induced epilepsy.
Where it's running
-
Remote study conducted nationwide; all participation occurs via smartphone app at home.
Princeton, New Jersey, United States Recruiting
Study contacts
- Study coordinator: Myrthe J. Ottenhoff, MD, PhD
- Email: study@blinklab.org
- Phone: 908-824-3471
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AdiaVita and glutathione for autism in kids and teens
This study tests whether adding AdiaVita (cord-blood stem cells and exosomes) to glutathione helps improve ASD symptoms in children and other participants compared with glutathione alone.
-
Do AdiaVita stem cells plus glutathione help kids with autism more than glutathione alone?
This 12-month study tests whether adding AdiaVita stem cells and exosomes to glutathione helps children aged 3–12 with autism more than glutathione alone.
-
Museum visits to support social and emotional well‑being in autistic adults
This study tests whether visiting the National Taiwan Museum can help improve social participation and well-being for autistic adults aged 18–50.
-
Two-week intensive brain-focused therapy program for children with neurodevelopmental and chromosomal conditions
This program will try a two-week, individualized multimodal neurorehabilitation approach for children about 4–12 years old with neurodevelopmental or chromosomal conditions to see if it improves attention, motor skills, communication, and daily functioning.
-
Gut barrier and gut microbes in children with autism
This trial will test whether a one-month course of postbiotic supplements can improve gut symptoms and behavior in children with autism aged 3–8.
-
Trauma‑Focused Cognitive Behavioral Therapy adapted for autistic children and teens (pilot implementation)
This pilot will try TF‑CBT adapted for autistic children and teens with trauma-related symptoms to see if community mental health clinicians can deliver it and families find it acceptable.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.